medigraphic.com
ISSN 1561-3054 (Digital)

2021, Número 2

<< Anterior

Rev Cubana Med Trop 2021; 73 (2)


Severidad de COVID-19 en África Sub-Sahariana y el uso sistemático de drogas antimaláricas

Fonte GL, Ginori GM, García MG, Sarmiento RME, Acosta DA

Idioma: Ingles.
Referencias bibliográficas: 34
Paginas: 1-8
Archivo PDF: 267.50 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Coronavirus press conference, 11 February 2020. Geneva: WHO; 2020 [acceso: 16/02/2021]. Disponible en: Disponible en: https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-full-press-conference-11feb 2020-final.pdf?sfvrsn=e2019136_2

  2. World Health Organization. Virtual press conference on COVID-19, 11 March 2020. Geneva: WHO; 2020 [acceso: 16/02/2021]. Disponible en: Disponible en: https://www.who.int/docs/defaultsource/coronaviruse/transcripts/who-audio-emergencies-coronavirus-fullpress-conference-11feb2020-final.pdf?sfvrsn=e2019136_2

  3. World Health Organization. Coronavirus disease 2019 (COVID-19): Weekly Epidemiological Update, 28 March 2021. Geneva: WHO; 2020 [acceso: 30/03/2021]. Disponible en: Disponible en: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210330_weekly_epi_update_33.pdf

  4. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20:269-70. DOI: https://doi.org/10.1038/s41577-020-0308-3

  5. Mbow M, Lell B, Jochems SP, Cisse B, Mboup S, Dewals DG, et al. COVID-19 in Africa: Dampening the storm? Science. 2020;369:624-26. Doi: https://doi.org/10.1126/science.abd3902

  6. Napoli P, Nioi M. Global spread of Coronavirus Disease 2019 and Malaria: An epidemiological paradox in the early stage of a pandemic. J Clin Med. 2020;9:1138. DOI: https://doi.org/10.3390/jcm9041138

  7. Haider N, Yavlinsky A, Simons D. Passengers' destinations from China: low risk of novel coronavirus (2019-nCoV) transmission into Africa and South America. Epidemiol Infect. 2020;148:e41. DOI: https://doi.org/10.1017/S0950268820000424

  8. Diop BZ, Ngom M, Pougué Biyong C, Pougué Boyong JN. The relatively young and rural population may limit the spread and severity of COVID-19 in Africa: a modelling study. BMJ Glob Health. 2020;5:e002699. DOI: https://doi.org/10.1136/bmjgh-2020-002699

  9. Cao Y, Li L, Feng Z. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020;6:11. DOI: https://doi.org/10.1038/s41421-020-0147-1

  10. Yang X, Dong N, Wai-Chi Chan E, Chen S. Genetic cluster analysis of SARS-CoV-2 and the identification of those responsible for the major outbreaks in various countries. Emerg Microb Infect. 2020;9:1287-99. DOI: https://doi.org/10.1080/22221751.2020.1773745

  11. Ahmed S, Quadeer A, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV Immunological Studies. Viruses. 2020;12:254. https://doi.org/10.3390/v12030254

  12. Grifoni A, Weiskopf D. Ramirez SI. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020;181:1489-501. DOI: https://doi.org/10.1016/j.cell.2020.05.015

  13. Gursel M, Gursel I. Is global BCG vaccination- induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Allergy 2020; 75:1815-19. DOI: https://doi.org/10.1111/all.14345

  14. Acosta A, Fonte L, Sarmiento ME, Norazmi MN. Does our Mycobacteriome Influence COVID-19 Morbidity and Lethality? Front Microbiol. 2021;12:589165. DOI: https://doi.org/10.3389/fmicb.2021.589165

  15. Fonte L, Acosta A, Sarmiento ME, Ginori M, García G, Norazmi MN. COVID-19 lethality in Sub-Saharan Africa and helminth immune modulation. Front Immunol. 2020;11. DOI: https://doi.org/10.3389/fimmu.2020.574910

  16. World Health Organization. World malaria report, 2018 [acceso: 16/02/2021]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/275867/9789241565653-eng.pdf

  17. Abena P, Decloedt E, Bottieau E, Suleman F, Adejumo P, Sam-Agudu N, et al. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. Am J Trop Med. Hyg. 2020;102:1184-8. DOI: https://doi.org/10.4269/ajtmh.20-0290

  18. Shah RR. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. J Clin Pharm Ther. 2021;46:17-27. DOI: https://doi.org/10.1111/jcpt.13267

  19. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020:105938. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105938

  20. Golden EB, Cho HY, Hofman FM. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38:E12. Doi: https://doi.org/10.3171/2014.12.FOCUS14748

  21. Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a minireview. Clin Drug Investig. 2018;38:653-71. DOI: https://doi.org/10.1007/s40261-018-0656-y

  22. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;20. DOI: https://doi.org/10.1093/jac/dkaa114

  23. Ocan M, Akena D, Nsobya S, Kamya MR, Senono R, Kinengyere AA, et al. Persistence of chloroquine resistance alleles in malaria endemic countries: A systematic review of burden and risk factors. Malar J. 2019;18. DOI: https://doi.org/10.1186/s12936-019-2716-z

  24. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. J Crit Care. 2020;59:176-90. DOI: https://doi.org/10.1016/j.jcrc.2020.06.019

  25. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177. https://doi.org/10.1016/j.antiviral.2020.104762

  26. Gendrot M, Duflot I, Boxberger M, Delandre O, Jardot P, Le Bideau M. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. Int J Infect Dis. 2020;99:447-54. DOI: https://doi.org/10.1016/j.ijid.2020.08.032

  27. Sargin G, Yavasoglu SI, Yavasoglu I. Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria? Medical Hypotheses. 2020;140. DOI: https://doi.org/10.1016/j.mehy.2020.109756

  28. Krishan K, Kanchan T. Novel Coronavirus (SARS-CoV-2) resistance in African populations: A cause worth exploring. Acta Biomed. 2020;91:e2020023. DOI: https://doi.org/10.23750/abm.v91i3.9872

  29. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2003;2:69. DOI: https://doi.org/10.1186/1743-422X-2-69

  30. Chatterjee P, Anand T, Singh KJ, Rasaily R, Singh R, Das S, et al. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. Indian J Med Res. 2020;151:459. DOI: https://doi.org/10.4103/ijmr.IJMR_2234_20

  31. Izoulet M. Countries which primarily use antimalarial drugs as COVID-19 treatment see slower dynamic of daily deaths. April 14, 2020. DOI: https://doi.org/10.2139/ssrn.3575899

  32. Eastman R, Fidock D. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7:764-74. DOI: https://doi.org/10.1038/nrmicro2239

  33. Gentry C, Humphrey M, Thind S, Hendrickson S, Kurdgelashvili G, Williams R. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol. 2020;2:e689-97. DOI: https://doi.org/10.1016/S2665-9913(20)30305-2

  34. Lee Z, Rayner C, Forrest J, Nachega J, Senchaudhuri E, Mills E. The rise and fall of hydroxychloroquine for the treatment and prevention of COVID-19. Am J Trop Med Hyg. 2021;104:35. DOI: https://doi.org/10.4269/ajtmh.20-1320




2020     |     www.medigraphic.com